Colombel 1999.

Methods	Randomized active comparator trial. Study participants and investigators were not blinded Intention to treat not performed 6 week trial
Participants	Patients aged >18 with acute ileal or colonic CD with no need for steroid treatment and a CDAI between 150 and 300 (N = 40)
Interventions	Oral ciprofloxacin 500 mg BID (n = 18) or oral mesalazine 2g BID (n = 22) for 6 weeks
Outcomes	Primary outcome: Clinical remission (CDAI ≤ 150) at 6 weeks Secondary outcomes: Partial remission (CDAI ≤ 150 but change in CDAI between 50‐75), treatment failure (increase in CDAI value or insufficient improvement at week 3 with change in CDAI > 50 or absence of complete or partial remission at week 6)
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not discussed
Allocation concealment (selection bias)	Unclear risk	Not discussed
Blinding of participants and personnel (performance bias) All outcomes	High risk	Trial was not blinded
Blinding of outcome assessment (detection bias) All outcomes	High risk	Trial was not blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	Two patients stopped treatment in ciprofloxacin group (one for intolerance, one for personal reasons) One patient was lost to follow up in mesalamine group
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	No other apparent sources of bias